Aquestive Therapeutics (NASDAQ:AQST) Price Target Raised to $10.00 at HC Wainwright

Aquestive Therapeutics (NASDAQ:AQST) had its price objective raised by stock analysts at HC Wainwright from $9.00 to $10.00 in a report issued on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 110.08% from the stock’s previous close.

Separately, JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research report on Monday, August 12th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $8.67.

Aquestive Therapeutics Stock Performance

Shares of AQST stock opened at $4.76 on Monday. The firm’s 50-day moving average is $4.26 and its 200-day moving average is $3.68. The stock has a market cap of $433.35 million, a price-to-earnings ratio of -11.33 and a beta of 2.84. Aquestive Therapeutics has a 52-week low of $1.25 and a 52-week high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.08. The firm had revenue of $20.10 million during the quarter, compared to the consensus estimate of $12.62 million. During the same period in the previous year, the company posted ($0.10) earnings per share. Sell-side analysts predict that Aquestive Therapeutics will post -0.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Victory Capital Management Inc. acquired a new stake in shares of Aquestive Therapeutics during the 2nd quarter worth approximately $27,000. PFG Investments LLC boosted its position in shares of Aquestive Therapeutics by 22.9% during the 2nd quarter. PFG Investments LLC now owns 59,000 shares of the company’s stock worth $153,000 after acquiring an additional 11,000 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Aquestive Therapeutics during the 1st quarter worth approximately $54,000. Financial Advocates Investment Management boosted its position in shares of Aquestive Therapeutics by 70.0% during the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after acquiring an additional 14,000 shares in the last quarter. Finally, Lazard Asset Management LLC boosted its position in shares of Aquestive Therapeutics by 115.5% during the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after acquiring an additional 15,601 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.